Atividade antidiabética da 4-Metoxichalcona isolada e nanoencapsulada
Loading...
Date
Authors
Advisor(s)
Co-advisor(s)
Committee members
Borges, Rosivaldo dos Santos
Souza, Tatiane Pereira de
Menezes, Irwin Rose Alencar de
Carvalho, Rosany Piccolotto
Souza, Tatiane Pereira de
Menezes, Irwin Rose Alencar de
Carvalho, Rosany Piccolotto
Graduate program
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal do Amazonas
Type
Access rights
DOI
Resumo (Portuguese)
O diabetes mellitus, uma alteração metabólica resultante de defeitos na secreção ou produção
de insulina, tornou-se um sério problema de saúde pública em todo o mundo. Dadas as
implicações das alterações metabólicas causadas pela diabetes na sociedade, economia e
qualidade de vida, a busca por novas alternativas terapêuticas para essa doença é de extrema
importância. Nesse contexto, o presente estudo teve como objetivo avaliar a atividade
antidiabética da 4-metoxichalcona isolada (MPP) e de sua formulação nanoencapsulada (NC),
por meio de ensaios in sílico, in vitro e in vivo. Inicialmente, a MPP foi sintetizada utilizando a
reação de condensação de Claisen-Schmidt e, posteriormente, caracterizada e quantificada por
RMN e espectrometria de massas. A nanoencapsulação do MPP resultou em uma formulação
estável e de liberação prolongada, com características favoráveis, incluindo uma distribuição
monomodal com tamanho de 187±3,85 nm, potencial zeta de -19,9 ± 0,72 mV, índice de
polidispersão de 0,21 ± 0,007 e condutividade de 0,041 ± 0,004 mS. Essa formulação
demonstrou estabilidade em ampla faixa de temperaturas (10 ̊C a 80 ̊C) e pH (1 a 5). A MPP
apresentou resultados promissores, demonstrando ausência de toxicidade tanto in vitro quanto
in vivo. Além disso, exibiu efeito hipoglicemiante em camundongos saudáveis e diabéticos
durante o teste de tolerância oral à glicose (TTOG), embora não tenha apresentado o mesmo
efeito no teste de tolerância oral à sacarose (TTOS). A administração oral tanto da MPP isolada
quanto de sua formulação nanoencapsulada demonstrou efeito hipoglicemiante em
camundongos diabéticos após tratamento de 7 semanas. Os níveis de glicemia obtidos com a
nanocápsula contendo MPP (NC10 = 166±58) na dose de 10 mg kg-1 pc, metformina (MET200
= 199±64) e MPP (MPP200 = 123±44) na dose de 200 mg kg-1 pc foram estatisticamente
equivalentes ao grupo não diabético (GN = 121±15), indicando que a nanoencapsulação
potencializou em 20 vezes o efeito antidiabético da MPP. Além disso, foi observado um efeito
antiglicante in vitro, e esses resultados foram corroborados pela redução dos níveis de HbA1c
(%) nos grupos MET200, MPP200 e NC10, alcançando níveis comparáveis ao grupo não
diabético (GN). É relevante destacar que o controle da glicemia foi alcançado sem causar dano
hepático, conforme comprovado pelas baixas concentrações de malonaldeído (μmol/g) e pela
histologia hepática. Esses resultados são de extrema relevância, uma vez que a MPP é uma
molécula de baixo custo e de fácil obtenção. O desenvolvimento de uma nanoformulação ativa
contendo essa molécula mostra-se como uma excelente opção terapêutica para o tratamento
do diabetes. Assim, esse estudo contribui significativamente para a busca de novas
abordagens farmacológicas no combate a essa doença metabólica crônica. Entretanto, são
necessárias futuras investigações e ensaios clínicos para validar completamente o potencial
terapêutico e a segurança dessa nanoformulação, de forma a viabilizar sua aplicação clínica e
seu potencial como um medicamento eficaz no tratamento do diabetes mellitus.
Abstract
Diabetes mellitus, a metabolic disorder resulting from defects in insulin secretion or production, has become a serious public health problem worldwide. Given the implications of metabolic alterations caused by diabetes on society, economy, and quality of life, the search for new therapeutic alternatives for this disease is of utmost importance. In this context, the present study aimed to evaluate the antidiabetic activity of isolated 4-methoxychalcone (MPP) and its nanoencapsulated formulation (NC), through in silico, in vitro, and in vivo assays. Initially, MPP was synthesized using the Claisen-Schmidt condensation reaction and subsequently characterized and quantified by NMR and mass spectrometry. The nanoencapsulation of MPP resulted in a stable and sustained release formulation with favorable characteristics, including a monomodal distribution with a size of 187±3.85 nm, zeta potential of -19.9 ± 0.72 mV, polydispersity index of 0.21 ± 0.007, and conductivity of 0.041 ± 0.004 mS. This formulation demonstrated stability over a wide range of temperatures (10 ˚C to 80 ˚C) and pH (1 to 5). MPP showed promising results, demonstrating no toxicity both in vitro and in vivo. Furthermore, it exhibited hypoglycemic effects in both healthy and diabetic mice during the oral glicose tolerance test (TTOG), although it did not have the same effect in the oral sucrose tolerance test (TTOS). Oral administration of both isolated MPP and its nanoencapsulated formulation demonstrated hypoglycemic effects in diabetic mice after 7 weeks of treatment. The glycemia levels obtained with the MPP-containing nanocapsule (NC10 = 166±58) at a dose of 10 mg/kg bw, metformin (MET200 = 199±64), and MPP (MPP200 = 123±44) at a dose of 200 mg/kg bw were statistically equivalent to the non-diabetic group (GN = 121±15), indicating that nanoencapsulation potentiated the antidiabetic effect of MPP by 20 times. Additionally, an antiglycation effect was observed in vitro, and these results were confirmed by the reduction of HbA1c levels (%) in the MET200, MPP200, and NC10 groups, reaching levels comparable to the non-diabetic group (GN). Importantly, glycemic control was achieved without causing hepatic damage, as evidenced by the low malondialdehyde concentrations (µmol/g) and liver histology. These results are of great significance, as MPP is a low-cost and readily available molecule. The development of an active nanoformulation containing this molecule proves to be an excellent therapeutic option for diabetes treatment. Thus, this study significantly contributes to the search for new pharmacological approaches in the fight against this chronic metabolic disease. However, further investigations and clinical trials are necessary to fully validate the therapeutic potential and safety of this nanoformulation, enabling its clinical application and potential as an effective medication for diabetes mellitus treatment.
Diabetes mellitus, a metabolic disorder resulting from defects in insulin secretion or production, has become a serious public health problem worldwide. Given the implications of metabolic alterations caused by diabetes on society, economy, and quality of life, the search for new therapeutic alternatives for this disease is of utmost importance. In this context, the present study aimed to evaluate the antidiabetic activity of isolated 4-methoxychalcone (MPP) and its nanoencapsulated formulation (NC), through in silico, in vitro, and in vivo assays. Initially, MPP was synthesized using the Claisen-Schmidt condensation reaction and subsequently characterized and quantified by NMR and mass spectrometry. The nanoencapsulation of MPP resulted in a stable and sustained release formulation with favorable characteristics, including a monomodal distribution with a size of 187±3.85 nm, zeta potential of -19.9 ± 0.72 mV, polydispersity index of 0.21 ± 0.007, and conductivity of 0.041 ± 0.004 mS. This formulation demonstrated stability over a wide range of temperatures (10 ˚C to 80 ˚C) and pH (1 to 5). MPP showed promising results, demonstrating no toxicity both in vitro and in vivo. Furthermore, it exhibited hypoglycemic effects in both healthy and diabetic mice during the oral glicose tolerance test (TTOG), although it did not have the same effect in the oral sucrose tolerance test (TTOS). Oral administration of both isolated MPP and its nanoencapsulated formulation demonstrated hypoglycemic effects in diabetic mice after 7 weeks of treatment. The glycemia levels obtained with the MPP-containing nanocapsule (NC10 = 166±58) at a dose of 10 mg/kg bw, metformin (MET200 = 199±64), and MPP (MPP200 = 123±44) at a dose of 200 mg/kg bw were statistically equivalent to the non-diabetic group (GN = 121±15), indicating that nanoencapsulation potentiated the antidiabetic effect of MPP by 20 times. Additionally, an antiglycation effect was observed in vitro, and these results were confirmed by the reduction of HbA1c levels (%) in the MET200, MPP200, and NC10 groups, reaching levels comparable to the non-diabetic group (GN). Importantly, glycemic control was achieved without causing hepatic damage, as evidenced by the low malondialdehyde concentrations (µmol/g) and liver histology. These results are of great significance, as MPP is a low-cost and readily available molecule. The development of an active nanoformulation containing this molecule proves to be an excellent therapeutic option for diabetes treatment. Thus, this study significantly contributes to the search for new pharmacological approaches in the fight against this chronic metabolic disease. However, further investigations and clinical trials are necessary to fully validate the therapeutic potential and safety of this nanoformulation, enabling its clinical application and potential as an effective medication for diabetes mellitus treatment.
Diabetes mellitus, a metabolic disorder resulting from defects in insulin secretion or production, has become a serious public health problem worldwide. Given the implications of metabolic alterations caused by diabetes on society, economy, and quality of life, the search for new therapeutic alternatives for this disease is of utmost importance. In this context, the present study aimed to evaluate the antidiabetic activity of isolated 4-methoxychalcone (MPP) and its nanoencapsulated formulation (NC), through in silico, in vitro, and in vivo assays. Initially, MPP was synthesized using the Claisen-Schmidt condensation reaction and subsequently characterized and quantified by NMR and mass spectrometry. The nanoencapsulation of MPP resulted in a stable and sustained release formulation with favorable characteristics, including a monomodal distribution with a size of 187±3.85 nm, zeta potential of -19.9 ± 0.72 mV, polydispersity index of 0.21 ± 0.007, and conductivity of 0.041 ± 0.004 mS. This formulation demonstrated stability over a wide range of temperatures (10 ˚C to 80 ˚C) and pH (1 to 5). MPP showed promising results, demonstrating no toxicity both in vitro and in vivo. Furthermore, it exhibited hypoglycemic effects in both healthy and diabetic mice during the oral glicose tolerance test (TTOG), although it did not have the same effect in the oral sucrose tolerance test (TTOS). Oral administration of both isolated MPP and its nanoencapsulated formulation demonstrated hypoglycemic effects in diabetic mice after 7 weeks of treatment. The glycemia levels obtained with the MPP-containing nanocapsule (NC10 = 166±58) at a dose of 10 mg/kg bw, metformin (MET200 = 199±64), and MPP (MPP200 = 123±44) at a dose of 200 mg/kg bw were statistically equivalent to the non-diabetic group (GN = 121±15), indicating that nanoencapsulation potentiated the antidiabetic effect of MPP by 20 times. Additionally, an antiglycation effect was observed in vitro, and these results were confirmed by the reduction of HbA1c levels (%) in the MET200, MPP200, and NC10 groups, reaching levels comparable to the non-diabetic group (GN). Importantly, glycemic control was achieved without causing hepatic damage, as evidenced by the low malondialdehyde concentrations (µmol/g) and liver histology. These results are of great significance, as MPP is a low-cost and readily available molecule. The development of an active nanoformulation containing this molecule proves to be an excellent therapeutic option for diabetes treatment. Thus, this study significantly contributes to the search for new pharmacological approaches in the fight against this chronic metabolic disease. However, further investigations and clinical trials are necessary to fully validate the therapeutic potential and safety of this nanoformulation, enabling its clinical application and potential as an effective medication for diabetes mellitus treatment.
Description
Keywords
Controlled term
Diabetes - Tratamento; Saúde pública
Sustainable Development Goals (SDG)
Citation
ROSALES ACHO, Leonard Domingo. Atividade antidiabética da 4-Metoxichalcona isolada e nanoencapsulada. 2023. 207 f. Tese (Doutorado em Inovação Farmacêutica) - Universidade Federal do Amazonas, Manaus (AM), 2023.
Endorsement
Review
Supplemented By
Referenced By
Rights and licensing
Acesso Aberto
